- Home
- QFIN vs AGIO Comparison
QFIN vs AGIO Comparison
Compare QFIN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- AGIO
- Stock Information
- Founded
- QFIN 2016
- AGIO 2007
- Country
- QFIN China
- AGIO United States
- Employees
- QFIN N/A
- AGIO N/A
- Industry
- QFIN Finance: Consumer Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- QFIN Finance
- AGIO Health Care
- Exchange
- QFIN Nasdaq
- AGIO Nasdaq
- Market Cap
- QFIN 3.1B
- AGIO 2.5B
- IPO Year
- QFIN 2018
- AGIO 2013
- Fundamental
- Price
- QFIN $18.04
- AGIO $24.46
- Analyst Decision
- QFIN Strong Buy
- AGIO Buy
- Analyst Count
- QFIN 3
- AGIO 7
- Target Price
- QFIN $37.07
- AGIO $37.33
- AVG Volume (30 Days)
- QFIN 2.5M
- AGIO 1.8M
- Earning Date
- QFIN 11-18-2025
- AGIO 10-30-2025
- Dividend Yield
- QFIN 8.37%
- AGIO N/A
- EPS Growth
- QFIN 40.93
- AGIO N/A
- EPS
- QFIN 6.93
- AGIO N/A
- Revenue
- QFIN $2,752,357,572.00
- AGIO $44,791,000.00
- Revenue This Year
- QFIN $17.10
- AGIO $25.57
- Revenue Next Year
- QFIN $6.28
- AGIO $153.24
- P/E Ratio
- QFIN $2.78
- AGIO N/A
- Revenue Growth
- QFIN 14.06
- AGIO 36.26
- 52 Week Low
- QFIN $18.01
- AGIO $22.24
- 52 Week High
- QFIN $48.94
- AGIO $62.45
- Technical
- Relative Strength Index (RSI)
- QFIN 26.63
- AGIO 25.59
- Support Level
- QFIN $21.59
- AGIO $22.24
- Resistance Level
- QFIN $22.88
- AGIO $46.00
- Average True Range (ATR)
- QFIN 1.01
- AGIO 2.20
- MACD
- QFIN -0.22
- AGIO -1.86
- Stochastic Oscillator
- QFIN 0.84
- AGIO 8.76
About QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.